Microbial Bioreactor Market

Microbial Bioreactor Market Size (2023 to 2028)

The global microbial bioreactor market size is predicted to be worth USD 6.48 billion by 2028 from USD 2.59 billion in 2023, growing at a CAGR of 20.1% from 2023 to 2028.

Currently, most micro-bioreactors are designed for batch processing and batch-fed; many companies are focusing on developing micro-bioreactors with continuous operation in chemostat mode. Micro-bioreactors constitute a multitude of downscaling needs for mammalian cell-based bioprocesses. Micro-bioreactor technology has allowed rapid progress in developing biotechnological processes and the study of various biological systems derived from industrial biotechnology and pharmaceutical biotechnology. Micro-bioreactors range in complexity, from simple micro-level-based systems to complex automated parallel bioreactors designed to scale up or down conventional, effective, and large-scale pilot bioprocesses.

MARKET DRIVERS:

In the current market scenario, the increasing adoption of single-use technologies, and the use of hybrid technologies: single-use and stainless steel, and the growing market for microbial bioreactors are driving the market growth. The growing demand for miniature bioreactors for research and the development of new technologies for personalized medicine is driving the market for microbial bioreactors during the forecast period. The growing demand for personalized medicines, coupled with a significant increase in the use of micro-bioreactors for the production of necessary therapies, is driving the market for microbial bioreactors during the forecast period. Most of the medicines under development by leading companies worldwide are related to personalized medicine and biomarkers. It is estimated that between 30 and 40% of the new drugs in development are being developed together with a biomarker that makes it relevant for treating diseases. The increased demand for patient-specific therapies and cell cultures also contributes to the growth of the microbial bioreactor market during the forecast period.

MARKET RESTRAINTS:

However, the availability of lower-priced alternatives and minimal availability in countries with weak economies are the main factors hampering the growth of the Microbial Bioreactor Market during the forecast period.

Impact of covid-19 on the Microbial Bioreactor Market:

COVID-19 is an unprecedented global public health emergency that has affected nearly every industry, hence the long-term effects are expected to affect industry growth during the forecast period. Ongoing research is expanding the research framework to ensure that underlying COVID-19 issues and potential future pathways are included. The report provides insights on COVID-19 considering changes in consumer behavior and demand, purchasing patterns, supply chain deviations, the dynamics of current market forces, and major interventions.

REPORT COVERAGE:

This market research report on the global microbial bioreactor market has been segmented and sub-segmented based on the scale range, end-user, suppliers, usage, and region.

Microbial Bioreactor Market – By Scale Range:

• 20L and 1500L

20L segment is leading with the dominant shares of the market in the coming years. By material, single-use bioreactors are expected to record the second-highest volume growth during the forecast period.

Microbial Bioreactor Market – By End-User:

• R&D departments
• Biopharmaceutical manufacturers

The R&D department segment is expected to record the highest growth rate during the forecast period due to the increased use of bioreactors in process development.

Microbial Bioreactor Market – By Suppliers:

• Original Equipment Manufacturers (OEM)
• System Integrators
• Engineering Procurement and Construction (EPC)

OEMs provide the equipment and configure the plumbing and integration, instrumentation, programming, and control.

Microbial Bioreactor Market – By Usage:

• Lab Scale
• Pilot Scale
• Full Scale

The lab-scale segment is holding with the highest shares of the market.

Microbial Bioreactor Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, the global microbial bioreactor market is expected to be dominated by North America and is expected to account for the largest market share in the microbial bioreactor market, followed by Europe and Asia-Pacific. North America is expected to experience significant growth during the forecast period due to factors such as the gradual increase in the number of existing pharmaceuticals, biopharmaceutical, and diverse industries in this region, the accessibility and acceptance of research grants, and government funding expanding the selection of smaller companies. Scale bioreactors for bioprocess advancement and high throughput testing.

Europe is expected to be the second most lucrative market for microbial bioreactors due to the increasing number of established pharmaceutical and biotechnology industries. Asia-Pacific is also expected to experience critical development during the estimated period. The Latin America and MEA regions are expected to drive the microbial bioreactor market during the forecast period due to the demand for bioreactor techniques and the advancement of the in vitro toxicity testing process and drug development.

KEY MARKET PARTICIPANTS:

The global microbial bioreactor market is concentrated on well-established players. Key players in the Microbial Bioreactor Market include Infors AG, m2p-labs GmbH, Eppendorf AG, Applikon Biotechnology, and Sartorius AG.

Sartorius AG had the largest share of the Microbial Bioreactor Market in terms of sales revenue in 2021.

RECENT MARKET HAPPENINGS:

• In May 2019, Sartorius Stedim Biotech (SSB), a leading international partner in the biopharmaceutical industry, introduces its new generation of the Ambr® 15 automated cell culture microreactor system. Generation 2 is the successor to the well-established Ambr® 15 cell culture system, which has been proven to reduce cell line development times and increase laboratory productivity dramatically. The new system offers greater flexibility and expanded capabilities for clone selection, feed and media optimization, and early process development.
• Pall Corporation (NYSE: PLL), a world leader in filtration, separation, and purification, announced the acquisition of MicroReactor Technologies, Inc. (MRT), a privately owned US biotechnology company. MRT has developed a reliable, easy-to-use, and cost-effective miniature bioreactor technology platform. The acquisition of MRT, with its proprietary approach to miniature high-performance bioreactor equipment and consumables.